{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T18:25:17Z","timestamp":1773685517427,"version":"3.50.1"},"reference-count":104,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T00:00:00Z","timestamp":1684368000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Brain and Behavior"],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>: There are limited therapeutic options for individuals with fibromyalgia. The aim of this study is to analyze changes in health\u2010related quality of life and incidence of adverse events of those prescribed cannabis\u2010based medicinal products (CBMPs) for fibromyalgia.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>: Patients treated with CBMPs for a minimum of 1\u00a0month were identified from the UK Medical Cannabis Registry. Primary outcomes were changes in validated patient\u2010reported outcome measures (PROMs). A <jats:italic>p<\/jats:italic>\u2010value of &lt;.050 was deemed statistically significant.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>: In total, 306 patients with fibromyalgia were included for analysis. There were improvements in global health\u2010related quality of life at 1, 3, 6, and 12\u00a0months (<jats:italic>p<\/jats:italic>\u00a0&lt;\u00a0.0001). The most frequent adverse events were fatigue (<jats:italic>n<\/jats:italic>\u00a0=\u00a075; 24.51%), dry mouth (<jats:italic>n<\/jats:italic>\u00a0=\u00a069; 22.55%), concentration impairment (<jats:italic>n<\/jats:italic>\u00a0=\u00a066; 21.57%), and lethargy (<jats:italic>n<\/jats:italic>\u00a0=\u00a065; 21.24%).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>: CBMP treatment was associated with improvements in fibromyalgia\u2010specific symptoms, in addition to sleep, anxiety, and health\u2010related quality of life. Those who reported prior cannabis use appeared to have a greater response. CBMPs were generally well\u2010tolerated. These results must be interpreted within the limitations of study design.<\/jats:p><\/jats:sec>","DOI":"10.1002\/brb3.3072","type":"journal-article","created":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T14:54:11Z","timestamp":1684421651000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Assessment of clinical outcomes in patients with fibromyalgia: Analysis from the UK Medical Cannabis Registry"],"prefix":"10.1002","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6010-2629","authenticated-orcid":false,"given":"Claire","family":"Wang","sequence":"first","affiliation":[{"name":"Medical Cannabis Research Group, Department of Surgery and Cancer Imperial College London  London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Erridge","sequence":"additional","affiliation":[{"name":"Medical Cannabis Research Group, Department of Surgery and Cancer Imperial College London  London UK"},{"name":"Sapphire Medical Clinics  London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carl","family":"Holvey","sequence":"additional","affiliation":[{"name":"Sapphire Medical Clinics  London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ross","family":"Coomber","sequence":"additional","affiliation":[{"name":"Sapphire Medical Clinics  London UK"},{"name":"St. George's Hospital NHS Trust  London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Azfer","family":"Usmani","sequence":"additional","affiliation":[{"name":"Sapphire Medical Clinics  London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed","family":"Sajad","sequence":"additional","affiliation":[{"name":"Sapphire Medical Clinics  London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rahul","family":"Guru","sequence":"additional","affiliation":[{"name":"Sapphire Medical Clinics  London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wendy","family":"Holden","sequence":"additional","affiliation":[{"name":"Sapphire Medical Clinics  London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James J.","family":"Rucker","sequence":"additional","affiliation":[{"name":"Sapphire Medical Clinics  London UK"},{"name":"Department of Psychological Medicine Kings College London  London UK"},{"name":"South London &amp; Maudsley NHS Foundation Trust  London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael W.","family":"Platt","sequence":"additional","affiliation":[{"name":"Medical Cannabis Research Group, Department of Surgery and Cancer Imperial College London  London UK"},{"name":"Sapphire Medical Clinics  London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikael H.","family":"Sodergren","sequence":"additional","affiliation":[{"name":"Medical Cannabis Research Group, Department of Surgery and Cancer Imperial College London  London UK"},{"name":"Sapphire Medical Clinics  London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,5,18]]},"reference":[{"issue":"1","key":"e_1_2_9_2_1","first-page":"105","article-title":"The Second International Congress on Controversies in Fibromyalgia; 12\u201013 March 2020, Berlin, Germany","volume":"38","author":"Ablin J. N.","year":"2020","journal-title":"Clinical and Experimental Rheumatology"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.3389\/FNBEH.2011.00034"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.2147\/JMDH.S104807"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.3389\/FPLS.2016.00019\/BIBTEX"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.10436"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.PEC.2008.06.005"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/S11920\u2010017\u20100775\u20109"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.7326\/AITC202003030"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.5152\/eurjrheum.2017.17025"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/426130"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.36076\/ppj.2008\/11\/S105"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpa.2020.08.010"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/SJ.BJP.0704327"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.JPAIN.2020.12.001"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003786.pub2"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1186\/s42238\u2010020\u201000024\u20102"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/S00213\u2010008\u20101168\u2010X"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1136\/ARD.2007.071522"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/PM\/PNAA303"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/NRRHEUM.2015.56"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.MAYOCP.2015.03.014"},{"key":"e_1_2_9_23_1","unstructured":"ClinicalTrials.gov. (2021).The effect of central sensitization on treatment response in patients with fibromyalgia.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05020600"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012188.pub2"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/SJ.BJP.0705920"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/NEU.20080"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/1529\u20100131(200008)13:4<198::AID\u2010ANR4>3.0.CO;2\u2010P"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.5435\/JAAOSGLOBAL\u2010D\u201017\u201000088"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1177\/1756284820977402"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/NPR2.12183"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.JPAIN.2009.01.258"},{"key":"e_1_2_9_32_1","volume-title":"New Clinical Fibromyalgia Diagnostic Criteria \u2013 Part 1","author":"Fibromyalgia Network"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.NEUINT.2020.104673"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PONE.0018440"},{"issue":"1","key":"e_1_2_9_35_1","first-page":"53","article-title":"Adding medical cannabis to standard analgesic treatment for fibromyalgia: A prospective observational study","volume":"38","author":"Giorgi V.","journal-title":"Clinical and Experimental Rheumatology"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.MAYOCP.2016.02.002"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2021.174089"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/J.1521\u20100391.2013.12003.X"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9113747"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02244012"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0000000000000702"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1097\/AJP.0B013E3182321AD8"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.3389\/FPHAR.2016.00108"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1002\/JCPH.1961"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1097\/FBP.0B013E3283474A6D"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.7759\/CUREUS.17332"},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.socscimed.2019.06.005"},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.1007\/S00296\u2010014\u20103208\u20107"},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.18773\/AUSTPRESCR.2017.056"},{"key":"e_1_2_9_50_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.MCG.0000139029.00451.C7"},{"key":"e_1_2_9_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0304\u20103959(98)00154\u20107"},{"key":"e_1_2_9_52_1","doi-asserted-by":"publisher","DOI":"10.1590\/1516\u20104446\u20102017\u20100015"},{"key":"e_1_2_9_53_1","doi-asserted-by":"publisher","DOI":"10.18553\/JMCP.2016.22.3.263"},{"key":"e_1_2_9_54_1","doi-asserted-by":"publisher","DOI":"10.1124\/MOL.105.015644"},{"key":"e_1_2_9_55_1","doi-asserted-by":"publisher","DOI":"10.1097\/MLR.0B013E318160D093"},{"key":"e_1_2_9_56_1","doi-asserted-by":"publisher","DOI":"10.1093\/PM\/PNAA396"},{"key":"e_1_2_9_57_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis\u20102016\u2010209724"},{"key":"e_1_2_9_58_1","doi-asserted-by":"publisher","DOI":"10.20960\/NH.703"},{"key":"e_1_2_9_59_1","doi-asserted-by":"publisher","DOI":"10.5554\/22562087.E980"},{"key":"e_1_2_9_60_1","doi-asserted-by":"publisher","DOI":"10.1186\/S42238\u2010021\u201000060\u20106"},{"key":"e_1_2_9_61_1","unstructured":"National Cancer Institute. (2009).Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0.http:\/\/www.meddramsso.com"},{"key":"e_1_2_9_62_1","unstructured":"National Institute for Health and Care Excellence. (2019).Position statement on use of the EQ\u20105D\u20105L value set for England.https:\/\/www.nice.org.uk\/about\/what\u2010we\u2010do\/our\u2010programmes\/nice\u2010guidance\/technology\u2010appraisal\u2010guidance\/eq\u20105d\u20105l"},{"key":"e_1_2_9_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.PBB.2015.11.002"},{"key":"e_1_2_9_64_1","doi-asserted-by":"publisher","DOI":"10.1186\/S13643\u2010020\u201001425\u20103\/TABLES\/1"},{"key":"e_1_2_9_65_1","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0B013E3182863447"},{"key":"e_1_2_9_66_1","doi-asserted-by":"publisher","DOI":"10.2174\/1573397113666170502152955"},{"key":"e_1_2_9_67_1","doi-asserted-by":"publisher","DOI":"10.1054\/PLEF.2001.0341"},{"key":"e_1_2_9_68_1","doi-asserted-by":"publisher","DOI":"10.1159\/000517857"},{"key":"e_1_2_9_69_1","doi-asserted-by":"publisher","DOI":"10.1300\/J094V09N03_10"},{"key":"e_1_2_9_70_1","doi-asserted-by":"publisher","DOI":"10.1007\/S10620\u2010007\u20100123\u20108"},{"key":"e_1_2_9_71_1","doi-asserted-by":"publisher","DOI":"10.1093\/AJE\/KWQ433"},{"key":"e_1_2_9_72_1","doi-asserted-by":"publisher","DOI":"10.1213\/ANE.0B013E3182707859"},{"key":"e_1_2_9_73_1","doi-asserted-by":"publisher","DOI":"10.1038\/SJ.BJP.0703850"},{"key":"e_1_2_9_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.MEHY.2005.08.026"},{"issue":"9","key":"e_1_2_9_75_1","first-page":"1916","article-title":"Clinically important changes in pain severity on VAS","volume":"65","author":"Sadovsky R.","year":"2002","journal-title":"American Family Physician"},{"key":"e_1_2_9_76_1","doi-asserted-by":"publisher","DOI":"10.3390\/JCM8060807"},{"key":"e_1_2_9_77_1","doi-asserted-by":"publisher","DOI":"10.1185\/030079906x112651"},{"key":"e_1_2_9_78_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22083891"},{"key":"e_1_2_9_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.JPAIN.2007.09.002"},{"key":"e_1_2_9_80_1","doi-asserted-by":"publisher","DOI":"10.1097\/j.pain.0000000000002550"},{"issue":"3","key":"e_1_2_9_81_1","first-page":"198","article-title":"Clinical endocannabinoid deficiency (CECD) revisited: Can this concept explain the therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment\u2010resistant conditions?","volume":"35","author":"Smith S. C.","year":"2014","journal-title":"Neuro Endocrinology Letters"},{"key":"e_1_2_9_82_1","doi-asserted-by":"publisher","DOI":"10.5664\/JCSM.7478"},{"key":"e_1_2_9_83_1","doi-asserted-by":"publisher","DOI":"10.1001\/ARCHINTE.166.10.1092"},{"key":"e_1_2_9_84_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0304\u20103959(00)00432\u20102"},{"key":"e_1_2_9_85_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010585.pub2"},{"key":"e_1_2_9_86_1","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/6541798"},{"key":"e_1_2_9_87_1","doi-asserted-by":"publisher","DOI":"10.1007\/S11916\u2010019\u20100803\u2010Z"},{"key":"e_1_2_9_88_1","doi-asserted-by":"publisher","DOI":"10.1097\/J.PAIN.0000000000001464"},{"key":"e_1_2_9_89_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.JVAL.2012.02.008"},{"key":"e_1_2_9_90_1","doi-asserted-by":"publisher","DOI":"10.1186\/1477\u20107525\u20106\u20108\/TABLES\/4"},{"key":"e_1_2_9_91_1","doi-asserted-by":"publisher","DOI":"10.1186\/AR4395"},{"key":"e_1_2_9_92_1","doi-asserted-by":"publisher","DOI":"10.2471\/BLT.07.045120"},{"key":"e_1_2_9_93_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.01259"},{"key":"e_1_2_9_94_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011694.pub2"},{"key":"e_1_2_9_95_1","doi-asserted-by":"publisher","DOI":"10.1136\/BMJ.N1034"},{"key":"e_1_2_9_96_1","doi-asserted-by":"publisher","DOI":"10.1503\/CMAJ.071178"},{"key":"e_1_2_9_97_1","doi-asserted-by":"publisher","DOI":"10.1213\/ANE.0B013E3181C76F70"},{"key":"e_1_2_9_98_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.ECLINM.2019.10.001"},{"key":"e_1_2_9_99_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010292.pub2"},{"key":"e_1_2_9_100_1","doi-asserted-by":"publisher","DOI":"10.1089\/CAN.2016.0025"},{"key":"e_1_2_9_101_1","unstructured":"Wipfler K. Simon T. Katz P. Wolfe F. &Michaud K.(2019).Cannabis use among patients in a large US rheumatic disease registry. ACR Meeting Abstracts.https:\/\/acrabstracts.org\/abstract\/cannabis\u2010use\u2010among\u2010patients\u2010in\u2010a\u2010large\u2010us\u2010rheumatic\u2010disease\u2010registry"},{"key":"e_1_2_9_102_1","doi-asserted-by":"publisher","DOI":"10.3899\/JRHEUM.100594"},{"key":"e_1_2_9_103_1","doi-asserted-by":"publisher","DOI":"10.1002\/ACR.20140"},{"issue":"6","key":"e_1_2_9_104_1","first-page":"846","article-title":"Towards a model of pathophysiology of fibromyalgia: Aberrant central pain mechanisms with peripheral modulation","volume":"19","author":"Yunus M. B.","year":"1992","journal-title":"The Journal of Rheumatology"},{"key":"e_1_2_9_105_1","doi-asserted-by":"publisher","DOI":"10.3389\/FPHAR.2017.00259"}],"container-title":["Brain and Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/brb3.3072","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T05:14:15Z","timestamp":1692335655000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/brb3.3072"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,18]]},"references-count":104,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["10.1002\/brb3.3072"],"URL":"https:\/\/doi.org\/10.1002\/brb3.3072","archive":["Portico"],"relation":{},"ISSN":["2162-3279","2162-3279"],"issn-type":[{"value":"2162-3279","type":"print"},{"value":"2162-3279","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,18]]},"assertion":[{"value":"2023-02-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-27","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e3072"}}